Wegovy's U.S. Supply Limited Due to High Demand
TL;DR Summary
Novo Nordisk, the maker of the weight-loss drug Wegovy, will limit the supply of starter doses in the US due to high demand. The drug, which was approved by the FDA in June, has shown significant weight loss results in clinical trials. The move to limit supply is due to supply chain constraints and the need to ensure adequate supply for patients who have already started treatment.
- Wegovy Maker to Limit Starter-Dose Supplies in U.S. as Demand Surges The Wall Street Journal
- Novo Nordisk cuts some US supply of obesity drug Wegovy to cope with demand Reuters
- Novo Nordisk stock dips as Wegovy sales miss, drug's US supply hit amid demand Seeking Alpha
- Novo Nordisk Stock Skids As Obesity Treatment Wegovy Misses Bullish Sales Calls | Investor's Business Daily Investor's Business Daily
- Novo Nordisk exec: oral weight-loss drug will have similar efficacy as Wegovy Reuters
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
0 min
vs 1 min read
Condensed
-52%
44 → 67 words
Want the full story? Read the original article
Read on The Wall Street Journal